No Data
Atea Pharmaceuticals(AVIR.US) Director Sells US$61,144.35 in Common Stock
Atea Pharmaceuticals(AVIR.US) Officer Sells US$4,024 in Common Stock
Morgan Stanley Initiates Atea Pharmaceuticals(AVIR.US) With Sell Rating, Announces Target Price $2
Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference